Church MK, Gradidge CF. Inhibition of histamine release from human lung in vitro by antihistamines and related drugs. Br J Pharmacol. 1980;69(4):663–7.
CAS
PubMed
PubMed Central
Google Scholar
Kirtane MV, Bhandari A, Narang P, Santani R. Cinnarizine: a contemporary review. Indian J Otolaryngol Head Neck Surg. 2019;71(2):1060–8.
PubMed
Google Scholar
Laporte JR, Capella D. Useless drugs are not placebos: lessons from flunarizine and cinnarizine. Lancet. 1986;2(8511):853–4.
CAS
PubMed
Google Scholar
Capellà D, Laporte JR, Castel JM, Tristán C, Cos A, Morales-Olivas FJ. Parkinsonism, tremor, and depression induced by cinnarizine and flunarizine. BMJ. 1988;297(6650):722–3.
PubMed
PubMed Central
Google Scholar
Herskovits E, Mangone C. Efectos adversos de tipo extrapiramidal y depresivo inducidos por cinarizina y flunarizina. Rev neurol Argent. 1987;13(2):131–2.
Google Scholar
Holmes B, Brogden R, Heel R, Speight T, Avery G. Flunarizine Drugs. 1984;27(1):6–44.
CAS
PubMed
Google Scholar
Pukhal’skaya TG, Kolosova OA, Men’shikov MY, Vein AM. Effects of calcium antagonists on serotonin-dependent aggregation and serotonin transport in platelets of patients with migraine. Bull Exp Biol Med. 2000;130(7):633–5.
PubMed
Google Scholar
Takada M, Kono T, Kitai ST. Flunarizine induces a transient loss of tyrosine hydroxylase immunoreactivity in nigrostriatal neurons. Brain Res. 1992;590(1-2):311–5.
CAS
PubMed
Google Scholar
Belforte JE, Magariños-Azcone C, Armando I, Buño W, Pazo JH. Pharmacological involvement of the calcium channel blocker flunarizine in dopamine transmission at the striatum. Parkinsonism Relat Disord. 2001;8(1):33–40.
CAS
PubMed
Google Scholar
Mena MA, Garcia de Yébenes MJ, Tabernero C, Casarejos MJ, Pardo B, Garcia de Yébenes J. Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol. 1995;18(5):410–26.
CAS
PubMed
Google Scholar
Kubo K, Matsuda Y, Kase H, Yamada K. Inhibition of calmodulin-dependent cyclic nucleotide phosphodiesterase by flunarizine, a calcium-entry blocker. Biochem Biophys Res Commun. 1984;124(2):315–21.
CAS
PubMed
Google Scholar
Meyboom RH, Ferrari MD, Dieleman BP. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet. 1986;2(8501):292.
CAS
PubMed
Google Scholar
De Melo-Souza S. Flunarizina, parkinsonismo e depressão. Goiania, Brazil: XI Brazilian neurology meeting; 1984.
Google Scholar
Martí Massó JF, Carrera N, de la Puente E. Parkinsonism possibly caused by cinnarizine. Med Clin (Barc). 1985;85(15):614–6.
Google Scholar
Chouza C, Scaramelli A, Caamaño J, De Medina O, Aljanati R, Romero S. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet. 1986;1(8493):1303–4.
CAS
PubMed
Google Scholar
Jankovic J, Tolosa E. Parkinson’s disease and movement disorders: Lippincott Williams & Wilkins; 2007.
Google Scholar
Association AP. Diagnostic and statistical manual of mental disorders (DSM-5®): American Psychiatric Pub; 2013.
Google Scholar
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.
CAS
PubMed
Google Scholar
de Vries E, Schoonvelde M, Schumacher G. No longer lost in translation: evidence that google translate works for comparative bag-of-words text applications. Polit Anal. 2018;26(4):417–30.
Google Scholar
D’Alessandro R, G B, G M. Side-effects of flunarizine. Lancet. 1986;2(8504):463-464.
R Giannaula, Micheli F, Fernandez Pardal MM. Reacciones extrapiramidales inducidas por flunarizina y cinnarizina. Abstracts of the XXVI Argentine meeting of Neurology, San Miguel de Tucuman, Argentina, October 22-25. 1986.
Martí Massó JF. Cinarizine and Parkinson’s disease. Double-blind placebo-controlled study. Neurologia. 1986;1(2):55–7.
PubMed
Google Scholar
Amery WK. Extrapyramidal symptoms and flunarizine. Funct Neurol. 1987;2(3):363–4.
CAS
PubMed
Google Scholar
Baldrati A, Albani F, de Carolis P, Sacquegna T. Essential tremor and flunarizine: description of a case. Cephalalgia. 1987;7(4):285.
CAS
PubMed
Google Scholar
Di Rosa AE, Morgante L, Meduri M, Musolino R, Leggiadro N, Coraci M, et al. Parkinson-like side effects during prolonged treatment with flunarizine. Funct Neurol. 1987;2(1):47–50.
PubMed
Google Scholar
Martí Massó JF, Obeso JA, Carrera N, Martínez-Lage JM. Aggravation of Parkinson’s disease by cinnarizine. J Neurol Neurosurg Psychiatry. 1987;50(6):804–5.
PubMed
PubMed Central
Google Scholar
De Michele G, Filla A, Coppola N, Mansi D, Brescia M, Buscaino GA. Extrapyramidal side-effects of flunarizine. Acta Neurol (Napoli). 1987;9(3):230–3.
Google Scholar
Micheli F, Pardal MF, Gatto M, Torres M, Paradiso G, Parera IC, et al. Flunarizine- and cinnarizine-induced extrapyramidal reactions. Neurology. 1987;37(5):881–4.
CAS
PubMed
Google Scholar
Assmann VC, Perquin WV, Touw DJ. Extrapyramidal movement disorders following the use of flunarizine. Ned Tijdschr Geneeskd. 1988;132(42):1940–3.
CAS
PubMed
Google Scholar
Bakchine S, Lacomblez L, Soubrié C. Extrapyramidal syndrome during treatment with flunarizine. Rev Neurol (Paris). 1988;144(12):833–4.
CAS
Google Scholar
Benvenuti F, Baroni A, Bandinelli S, Ferrucci L, Corradetti R, Pantaleo T. Flunarizine-induced parkinsonism in the elderly. J Clin Pharmacol. 1988;28(7):600–8.
CAS
PubMed
Google Scholar
Lugaresi A, Montagna P, Gallassi R, Lugaresi E. Extrapyramidal syndrome and depression induced by flunarizine. Eur Neurol. 1988;28(4):208–11.
CAS
PubMed
Google Scholar
De Marco P, Rossi G. Flunarizine and parkinson-like syndrome in a young man. Boll Lega Hal Epilessia, 62. 1988;63:227.
Martínez-Lage JM. Flunarizine (Sibelium) in the prophylaxis of migraine. An open, long-term, multicenter trial. Cephalalgia. 1988;8(8_suppl):15-20.
Moretti A, Lucantoni C. Flunarizine-induced parkinsonism: clinical report. Ital J Neurol Sci. 1988;9(3):295–7.
CAS
PubMed
Google Scholar
Di Rosa A. Extrapyramidal symptoms and flunarizine. Funct Neurol. 1988;3(2):237–8.
PubMed
Google Scholar
Rostin M, Montastruc JL, Guiraud-Chaumeil B, Rascol A. Outcome of an extrapyramidal syndrome during prophylactic treatment of migraine with flunarizine. Therapie. 1988;43(3):242.
CAS
PubMed
Google Scholar
Fontanari JL. A side effect of flunarizine: severe parkinsonism. Arq Neuropsiquiatr. 1989;47(3):352–4.
CAS
PubMed
Google Scholar
Gabellini AS, Martinelli P, Coccagna G. Drug-induced tremor of the tongue. Ital J Neurol Sci. 1989;10(1):89–91.
CAS
PubMed
Google Scholar
Hefner R, Fischer PA. Increase in Parkinson symptoms caused by calcium antagonists. Nervenarzt. 1989;60(3):187–8.
CAS
PubMed
Google Scholar
Jongerius AM, van Gool AR. Extrapyramidal movement disorders following administration of flunarizine. Ned Tijdschr Geneeskd. 1989;133(14):746–7.
CAS
PubMed
Google Scholar
Kuzuhara S, Kohara N, Ohkawa Y, Fuse S, Yamanouchi H. Parkinsonism, depression and akathisia induced by flunarizine, a calcium entry blockade--report of 31 cases. Rinsho Shinkeigaku. 1989;29(6):681–6.
CAS
PubMed
Google Scholar
Mangone CA, Herskovits E. Extrapyramidal and depressive side reactions with flunarizine and cinarizine. J Neurol Neurosurg Psychiatry. 1989;52(2):288–9.
CAS
PubMed
PubMed Central
Google Scholar
Micheli FE, Pardal MM, Giannaula R, Gatto M, Parera I, Paradiso G, et al. Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord. 1989;4(2):139–46.
CAS
PubMed
Google Scholar
Mukai E, Makino N, Fujishiro K. Magnetic resonance imaging of parkinsonism. Rinsho Shinkeigaku. 1989;29(6):720–5.
CAS
PubMed
Google Scholar
Petri H. Extrapyramidal movement disorders following the use of flunarizine. Ned Tijdschr Geneeskd. 1989;133(3):131.
CAS
PubMed
Google Scholar
Sa PN, Heinisch LM. Parkinson disease induced by flunarizine. Arq Neuropsiquiatr. 1989;47(4):471–3.
PubMed
Google Scholar
Centonze V, Magrone D, Vino M, Caporaletti P, Attolini E, Campanale G, et al. Flunarizine in migraine prophylaxis: efficacy and tolerability of 5 mg and 10 mg dose levels. Cephalalgia. 1990;10(1):17–24.
CAS
PubMed
Google Scholar
Micheli F, Gatto M, Lekhuniec E, Mangone C, Fernandez Pardal M, Pikielny R, et al. Treatment of Tourette’s syndrome with calcium antagonists. Clin Neuropharmacol. 1990;13(1):77–83.
CAS
PubMed
Google Scholar
Senard JM, Colomes M, Rostin M, Clanet M, Montastruc JL. Extrapyramidal syndromes caused by flunarizine. Apropos of 6 cases. Therapie. 1990;45(2):157–9.
CAS
PubMed
Google Scholar
Trevisol-Bittencourt P. Flunarizina induzindo parkinsonismo. Arq Cat Med. 1990;19(1):81–4.
Google Scholar
Fontanari JL. Discinesia tardia residual 24 meses após a suspensão do uso da flunarizina. Rev Bras Neurol. 1991;27(3):97–8.
Google Scholar
Giménez-Roldán S, Mateo D. Cinnarizine-induced parkinsonism. Susceptibility related to aging and essential tremor. Clin Neuropharmacol. 1991;14(2):156–64.
PubMed
Google Scholar
Rodríguez García JL, Arechaga US. Flunarizine-induced akathisia. Rev Clin Esp. 1991;188(7):384.
PubMed
Google Scholar
Wilder-Smith CH, Schimke J, Osterwalder B, Senn HJ. Cinnarizine for prevention of nausea and vomiting during platin chemotherapy. Acta Oncol. 1991;30(6):731–4.
CAS
PubMed
Google Scholar
García-Ruiz PJ, García de Yébenes J, Jiménez-Jiménez FJ, Vázquez A, García Urra D, Morales B. Parkinsonism associated with calcium channel blockers: a prospective follow-up study. Clin Neuropharmacol. 1992;15(1):19–26.
PubMed
Google Scholar
Morgante L, Rocca WA, Di Rosa AE, De Domenico P, Grigoletto F, Meneghini F, et al. Prevalence of Parkinson’s disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology. 1992;42(10):1901–7.
CAS
PubMed
Google Scholar
Negrotti A, Calzetti S, Sasso E. Calcium-entry blockers-induced parkinsonism: possible role of inherited susceptibility. Neurotoxicology. 1992;13(1):261–4.
CAS
PubMed
Google Scholar
Amancio E, Zymberg S, Peluso C. Parkinsonism and depression induced by flunarizine. Revista Brasileira de Medicina. 1993;50:1316.
Google Scholar
Anand KS, Thiagarajan A. Flunarizine induced akathisia and depression. Neurol India. 1993;41(4):239.
CAS
PubMed
Google Scholar
Cunha CA, Bittencourt PRM, Kohlscheen K-L, Mercer LM. Parkinsonisno reversível induzido por cinarizina e flunarizina. Rev méd Paraná. 1993;50(3/4):13–6.
Google Scholar
Curran T, Lang AE. Flunarizine in essential tremor. Clin Neuropharmacol. 1993;16(5):460–3.
CAS
PubMed
Google Scholar
Galhardo I, Coutinho MO, De Albuquerque ES. Medeiros LdO. Parkinson disease induced by flunarizine: report of a case. Arq Neuropsiquiatr. 1993;51(4):546–8.
CAS
PubMed
Google Scholar
Beghi E, Monticelli ML, Sessa A, Simone P. The prevalence of parkinsonism in Italy: an epidemiological survey of the disease in general practice. The Italian General Practitioner Study Group (IGPSG). Mov Disord. 1994;9(4):403–8.
CAS
PubMed
Google Scholar
Llau ME, Nguyen L, Senard JM, Rascol O, Montastruc JL. Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance. Rev Neurol (Paris). 1994;150(11):757–62.
CAS
Google Scholar
Anjaneyulu A, Mohandas S. Flunarizine induced parkinsonism : a report of two cases. Neurol India. 1995;43(4):217–8.
CAS
PubMed
Google Scholar
Baquero M, Domínguez-Sanz FJ, Burguera JA, Cruz Campos GA, Muñoz R. New forms of parkinsonism in hospice care. Rev Neurol. 1995;23(123):964–8.
CAS
PubMed
Google Scholar
Brücke T, Wöber C, Podreka I, Wöber-Bingöl C, Asenbaum S, Aull S, et al. D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J Cereb Blood Flow Metab. 1995;15(3):513–8.
PubMed
Google Scholar
Claps A. Parkinson’s disease secondary to flunarizine or other drugs. Rev Med Chil. 1995;123(8):1033–6.
CAS
PubMed
Google Scholar
Handforth A, Mai T, Treiman DM. Rising dose study of safety and tolerance of flunarizine. Eur J Clin Pharmacol. 1995;49(1-2):91–4.
CAS
PubMed
Google Scholar
Jiménez-Jiménez FJ, Ortí-Pareja M, Ayuso-Peralta L, Gasalla T, Cabrera-Valdivia F, Vaquero A, et al. Drug-induced parkinsonism in a movement disorders unit: a four-year survey. Parkinsonism Relat Disord. 1996;2(3):145–9.
PubMed
Google Scholar
Lee SJ, Lee WY. Three cases of flunarizine-induced Parkinsinism. J Korean Neurol Assoc. 1996;14(4):995.
Google Scholar
Martí Massó JF, Poza JJ. Drug-induced or aggravated parkinsonism: clinical signs and the changing pattern of implicated drugs. Neurologia. 1996;11(1):10–5.
PubMed
Google Scholar
Peña MA. Parkinsonismo farmacológico inducido por flunarizina y cinarizina. Rev otorrinolaringol cir cabeza cuello. 1996;56(2):81–3.
Google Scholar
Morgante L, Di Rosa AE, Savettieri G, Reggio A, Patti F, Salemi G, et al. Drug-induced parkinsonism: prevalence, clinical features and follow-up study in three Sicilian communities. J Neurol. 1996;243(3):293–5.
CAS
PubMed
Google Scholar
Vecchio I, Rampello L, Tornali C, Malaguarnera M, Raffaele R. Flunarizine and essential tremor in the elderly. Arch Gerontol Geriatr. 1996;22(Suppl 1):73–7.
PubMed
Google Scholar
Verspeelt J, De Locht P, Amery WK. Postmarketing study of the use of flunarizine in vestibular vertigo and in migraine. Eur J Clin Pharmacol. 1996;51(1):15–22.
CAS
PubMed
Google Scholar
Koukoulis A, Herrero JS, Gómez-Alonso J. Blepharospasm induced by flunarizine. J Neurol Neurosurg Psychiatry. 1997;63(3):412–3.
CAS
PubMed
PubMed Central
Google Scholar
Negrotti A, Calzetti S. A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism. Mov Disord. 1997;12(1):107–10.
CAS
PubMed
Google Scholar
Cardoso F, Camargos ST, Silva Júnior GA. Etiology of parkinsonism in a Brazilian movement disorders clinic. Arq Neuropsiquiatr. 1998;56(2):171–5.
CAS
PubMed
Google Scholar
Errea-Abad JM, Ara-Callizo JR, Aibar-Remón C. Drug-induced parkinsonism. Clinical aspects compared with Parkinson disease. Rev Neurol. 1998;27(155):35–9.
CAS
PubMed
Google Scholar
García-Ruiz PJ, Javier Jiménez-Jiménez F, García de Yébenes J. Calcium channel blocker-induced parkinsonism: clinical features and comparisons with Parkinson’s disease. Parkinsonism Relat Disord. 1998;4(4):211–4.
PubMed
Google Scholar
Martí-Massó JF, Poza JJ. Cinnarizine-induced parkinsonism: ten years later. Mov Disord. 1998;13(3):453–6.
PubMed
Google Scholar
Ortí-Pareja M, Jiménez-Jiménez FJ, Vázquez A, Catalán MJ, Zurdo M, Burguera JA, et al. Drug-induced tardive syndromes. Parkinsonism Relat Disord. 1999;5(1-2):59–65.
PubMed
Google Scholar
Stucchi-Portocarrero S, Vega-Dienstmaier JM, Saavedra JE, Sagástegui A. Akathisia, parkinsonism and depression induced by cinnarizine: a case report. Rev Neurol. 1999;28(9):876–8.
CAS
PubMed
Google Scholar
Argote E, Zamora T. Características clínicas y fármacos recibidos por los pacientes con diagnóstico de Parkinson. Colombia Médica. 1999;30(4):167–72.
Google Scholar
Vázquez-Alén P, Pérez-Gilabert Y, Mateo D, Giménez-Roldán S. A study made on a data base of 2,471 patients with Parkinson disease and disorders of movement in Health District 1 of the autonomous region of Madrid. Observed demographic changes over 8 year-period. Rev Neurol. 2000;30(7):635–40.
PubMed
Google Scholar
Schillevoort I, de Boer A, Roos R, Jansen P, Leufkens H. Chapter 4.3 Extrapyramidal syndromes associated with cinnarizine and flunarizine. In: Drug-induced extrapyramidal syndromes. Cologne: Prima Print; 2002.
Benito-León J, Bermejo-Pareja F, Rodríguez J, Molina JA, Gabriel R, Morales JM, et al. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord. 2003;18(3):267–74.
PubMed
Google Scholar
Fabiani G, Pastro PC, Froehner C. Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine. Arq Neuropsiquiatr. 2004;62(3b):784–8.
PubMed
Google Scholar
Martí Massó J-F, Martí I, Carrera N, Poza J-J, López de Munain A. Trimetazidine induces parkinsonism, gait disorders and tremor. Therapie. 2005;60(4):419–22.
PubMed
Google Scholar
Trevisol-Bittencourt P, Pioner L, Tomaselli P, Nahoum R, Tournier M, Collares C, et al. Parkinsonism at a nursing facility. J Neurol Sci. 2005.
Alonso-Navarro H, Jiménez-Jiménez FJ. Tardive blepharospasm associated with cinnarizine use. Clin Neuropharmacol. 2006;29(4):187–9.
PubMed
Google Scholar
Barbosa MT, Caramelli P, Maia DP, Cunningham MCQ, Guerra HL, Lima-Costa MF, et al. Parkinsonism and Parkinson’s disease in the elderly: a community-based survey in Brazil (the Bambuí study). Mov Disord. 2006;21(6):800–8.
PubMed
Google Scholar
Turner D, Lurie Y, Finkelstein Y, Schmid T, Gopher A, Kleid D, et al. Pediatric cinnarizine overdose and toxicokinetics. Pediatrics. 2006;117(5):e1067–e9.
PubMed
Google Scholar
Benito-León J, Louis ED, Bermejo-Pareja F, Neurological Disorders in Central Spain Study G. Risk of incident Parkinson’s disease and parkinsonism in essential tremor: a population based study. J Neurol Neurosurg Psychiatry. 2009;80(4):423–5.
PubMed
Google Scholar
Biary N, Al Deeb SM, Bahou Y. Long-term therapy of essential tremor with flunarizine. Eur Neurol. 1995;35(4):217–9.
CAS
PubMed
Google Scholar
Bisol LW, Brunstein MG, Ottoni GL, Ramos FLP, Borba DL, Daltio CS, et al. Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia. J Clin Psychiatry. 2008;69(10):1572–9.
CAS
PubMed
Google Scholar
Diaz-Corrales FJ, Sanz-Viedma S, Garcia-Solis D, Escobar-Delgado T, Mir P. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2010;37(3):556–64.
PubMed
Google Scholar
Louter M, Tromp SC. Parkinsonism due to the medication. Ned Tijdschr Geneeskd. 2009;153:A336-A.
Ma H-I, Kim J-H, Chu M-K, Oh M-S, Yu K-H, Kim J, et al. Diabetes mellitus and drug-induced parkinsonism: a case-control study. J Neurol Sci. 2009;284(1-2):140–3.
PubMed
Google Scholar
Mattos JP, Nicaretta DH, Rosso ALZ. Progressive supranuclear palsy-like syndrome induced by amiodarone and flunarizine. Arq Neuropsiquiatr. 2009;67(3B):909–10.
PubMed
Google Scholar
Munhoz RP, Werneck LC, Teive HAG. The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. Clin Neurol Neurosurg. 2010;112(5):431–5.
PubMed
Google Scholar
Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc J-L. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26(12):2226–31.
PubMed
Google Scholar
Kizilay F, Ekmekci B, Gungor H, Uysal H, Oh SJ. Flunarizine-induced fasciculation-myokymia. J Clin Neuromuscul Dis. 2011;12(4):246–7.
PubMed
Google Scholar
Masmoudi K, Masson H, Gras V, Andréjak M. Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases. Fundam Clin Pharmacol. 2012;26(2):198–203.
CAS
PubMed
Google Scholar
Arias AC, Reyes ED, Fernández JCD, Pérez RC, González LRA, Nogueira GC, et al. Depresión Mayor inducida por flunarizina. Associacion colombiana de Psiquiatria. 2012;07:11–2.
Google Scholar
Foubert-Samier A, Helmer C, Perez F, Le Goff M, Auriacombe S, Elbaz A, et al. Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology. 2012;79(15):1615–21.
CAS
PubMed
Google Scholar
Pioner LM. Relato de parkinsonismo induzido por cinarizina: reflexões sobre uma iatrogenia. Revista Espaço Acadêmico. 2012;12(136):122–9.
Google Scholar
Kim JS, Youn J, Shin H, Cho JW. Nonmotor symptoms in drug-induced parkinsonism and drug-naïve Parkinson disease. Can J Neurol Sci. 2013;40(1):36–41.
PubMed
Google Scholar
DR G, LE C, EL R, AL M. Flunarizine-induced parkinsonism. Brazilian Journal of Surgery and Clinical Research. 2014;7(2):25–7.
Google Scholar
Miguel R, Correia ASA, Bugalho P. Iatrogenic parkinsonism: the role of flunarizine and cinnarizine. J Park Dis. 2014;4(4):645–9.
CAS
Google Scholar
Otero S. Flunarizine and neuro-psychiatric symptoms in children and adolescents. J Pediatr Neurol. 2006;4(4):271–3.
CAS
Google Scholar
Krishnan Vengadaragava C, Raman K. A unique case of flunarizine induced extrapyramidal syndrome and depression. PTB Reports. 2016;2(2).
Lin H-L, Lin H-C, Tseng Y-F, Chen S-C, Hsu C-Y. Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study. Eur J Clin Pharmacol. 2017;73(3):365–71.
CAS
PubMed
Google Scholar
Munhoz RP, Bertucci Filho D, Teive HAG. Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype. Neurol Sci. 2017;38(2):319–24.
PubMed
Google Scholar
Nisticò R, Fratto A, Vescio B, Arabia G, Sciacca G, Morelli M, et al. Tremor pattern differentiates drug-induced resting tremor from Parkinson disease. Parkinsonism Relat Disord. 2016;25:100–3.
PubMed
Google Scholar
Sung YH, Noh Y, Lee J, Kim EY. Drug-induced parkinsonism versus idiopathic Parkinson disease: itility of nigrosome 1 with 3-T imaging. Radiology. 2016;279(3):849–58.
PubMed
Google Scholar
Jhang K-M, Huang J-Y, Nfor ON, Tung Y-C, Ku W-Y, Lee C-T, et al. Erratum to: Extrapyramidal symptoms after exposure to calcium channel blocker-flunarizine or cinnarizine. Eur J Clin Pharmacol. 2017;73(7):917.
PubMed
PubMed Central
Google Scholar
Lopez-Castellanos JR, Lopez-Contreras J, editors. Myoclonus and tremor induced by flunarizine and cinnarizine: a report of four cases in El Salvador. Movement Disorders; 2017.
Mathews SR, Badyal DK, Varghese A. Acute dystonia induced by prochlorperazine and cinnarizine. J Rational Pharmacother Res. 2017;3:53-4.
Yang YW, Hsieh TF, Li CI, Liu CS, Lin WY, Chiang JH, et al. Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine. 2017;96(3):e5921.
PubMed
PubMed Central
Google Scholar
Karsan N, Palethorpe D, Rattanawong W, Marin JC, Bhola R, Goadsby PJ. Flunarizine in migraine-related headache prevention: results from 200 patients treated in the UK. Eur J Neurol. 2018;25(6):811–7.
CAS
PubMed
Google Scholar
Liang C-Y, Yeh Y-C, Lee C-J, Chen Y-Y. Flunarizine and the risk of parkinsonism in a newly diagnosed type 2 diabetic population in Taiwan: a nested case-control study. J Clin Neurosci. 2018;50:281–6.
CAS
PubMed
Google Scholar
Byun JH, Cho H, Kim YJ, Kim JS, Baik JS, Jang S, et al. Trends in the prevalence of drug-induced parkinsonism in Korea. Yonsei Med J. 2019;60(8):760–7.
PubMed
PubMed Central
Google Scholar
Gallop F, Fosi T, Prabhakar P, Aylett SE. Flunarizine for headache prophylaxis in children with Sturge-Weber syndrome. Pediatr Neurol. 2019;93:27–33.
PubMed
Google Scholar
Jhang K-M, Huang J-Y, Nfor ON, Tung Y-C, Ku W-Y, Jan C-F, et al. Flunarizine related movement disorders: a nationwide population-based study. Sci Rep. 2019;9(1):1705.
PubMed
PubMed Central
Google Scholar
Kim S, Cheon S-M, Suh HS. Association between drug exposure and occurrence of parkinsonism in Korea: a population-based case-control study. Ann Pharmacother. 2019;53(11):1102–10.
CAS
PubMed
Google Scholar
Lin W, Lin C-L, Hsu CY, Wei C-Y. Flunarizine induced parkinsonism in migraine group: a nationwide population-based study. Front Pharmacol. 2019;10:1495.
PubMed
PubMed Central
Google Scholar
Teive HAG, Munhoz RP, Ferraz HB. Flunarizine and cinnarizine-induced parkinsonism: 25 years of de Melo-Souza’s syndrome. Arq Neuropsiquiatr. 2009;67(3B):957.
PubMed
Google Scholar
Teive HAG, Troiano AR, Germiniani FMB, Werneck LC. Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis. Parkinsonism Relat Disord. 2004;10(4):243–5.
PubMed
Google Scholar
Brugger F, Bhatia KP, Besag FM. Valproate-associated parkinsonism: a critical review of the literature. CNS drugs. 2016;30(6):527–40.
CAS
PubMed
Google Scholar
Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. 1998;32(6):692–8.
CAS
PubMed
Google Scholar
Lepping P, Delieu J, Mellor R, Williams JHH, Hudson PR, Hunter-Lavin C. Antipsychotic medication and oxidative cell stress: a systematic review. J Clin Psychiatry. 2011;72(3):273–85.
CAS
PubMed
Google Scholar
Blandina P, Munari L, Provensi G, Passani MB. Histamine neurons in the tuberomamillary nucleus: a whole center or distinct subpopulations? Front Syst Neurosci. 2012;6:33.
PubMed
PubMed Central
Google Scholar
Rupniak NM, Jenner P, Marsden CD. Acute dystonia induced by neuroleptic drugs. Psychopharmacology. 1986;88(4):403–19.
CAS
PubMed
Google Scholar
Jimenez-Jimenez FJ, Puertas I, de Toledo-Heras M. Drug-induced myoclonus. CNS drugs. 2004;18(2):93–104.
CAS
PubMed
Google Scholar